Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P16_37-63 peptide + Montanide ISA-51 VG
- Development stage
- Unknown
- Lead developer
- Oryx
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The combination of P16_37-63 peptide and Montanide ISA-51 VG is an investigational therapeutic cancer vaccine. The P16_37-63 peptide is derived from the cyclin-dependent kinase inhibitor p16(INK4a), a protein that is overexpressed in HPV-associated cancers but minimally expressed in normal tissues, making it a promising tumor-specific antigen. Montanide ISA-51 VG acts as an immunologic adjuvant to enhance immune responses. This combination has been evaluated in phase 1/2 clinical trials for safety and immunogenicity, showing induction of both cellular (CD4+ and CD8+ T cell) and humoral (antibody) immune responses without severe toxicities. The primary indication under investigation is HPV-associated cancers, including cervical, vulvar, vaginal, penile, anal cancers, and head and neck squamous cell carcinoma[1][2][3][4][5][8].
- Other names
- p16INK4a-derived peptide vaccinep-16INK4a-derived peptide vaccinep 16INK4a-derived peptide vaccinep16INK4a vaccinep-16INK4a vaccinep 16INK4a vaccineP16 37–63 peptide + Montanide ISA-51 VG
02
Targets
CDKN2A (Cyclin-dependent kinase inhibitor 2A)
Beyond the preview
Go deeper on P16_37-63 peptide + Montanide ISA-51 VG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P16_37-63 peptide + Montanide ISA-51 VG.